-+ 0.00%
-+ 0.00%
-+ 0.00%

TriSalus publishes investor presentation on pressure-enabled drug delivery for solid tumors

PUBT·04/15/2026 14:32:58
Listen to the news
TriSalus publishes investor presentation on pressure-enabled drug delivery for solid tumors
  • TriSalus highlighted Pressure Enabled Drug Delivery platform TriNav for locoregional infusion into solid tumors, targeting hepatocellular carcinoma and pancreatic cancer.
  • 2026 outlook calls for annual revenues of $60 million to $62 million.
  • U.S. addressable device market opportunity estimated at more than $2.5 billion annually.
  • Pipeline asset nelitolimod, delivered via PEDD to liver and pancreatic tumors, framed as adding $1 billion incremental upside if approved for combination use in pancreatic cancer.
  • Reimbursement support includes HCPCS mapping code C8004 with 2026 rate of $11,794, alongside procedure code C9797 with 2026 rate of $18,728.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.